Oppenheimer analyst Matthew Biegler initiated coverage of Tyra Biosciences with an Outperform rating and $17 price target. The firm expects TYRA-300 to yield better response rates than erdafitinib in metastatic urothelial carcionoma, or mUC, and calls the stock a "straightforward story that we believe is flying under investors’ radar."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly